상품명칭 |
아드리아마이시놀 |
별명 |
13-디하이드로독소루비신; 10-((3-아미노-2,3,6-트리데옥시-알파-L-릭소-헥소피라노실)옥시)-8-(1,2-디히드록시에틸)-7,8,9,10-테트라하이드로-6,8,11-트리하이드록시-1-메톡시-5,12-나프타세네디온; 5,12-나프타세네디온, 10-((3-아미노-2,3,6-트리데옥시-알파-L-릭소-헥소피라노실)옥시)-8-(1,2-디히드록시에틸)-7,8,9,10-테트라하이드로-6,8,11-트리하이드록시-1-메톡시-; 3-(1,2-디히드록시에틸)-3,5,12-트리하이드록시-10-메톡시-6,11-다이옥소-1,2,3,4,6,11-헥사하이드로테트라센-1-일-3-아미노-2,3,6-트리데옥시-L-릭소-헥소피라노사이드; (1S,3S)-3-[(1S)-1,2-디히드록시에틸]-3,5,12-트리하이드록시-10-메톡시-6,11-디옥소-1,2,3,4,6,11-헥사하이드로테트라센-1-일-3-아미노-2,3,6-트리데옥시-알파-L-릭소-헥소피라노사이드 염산염(1:1) |
영문 이름 |
adriamycinol;13-Dihydrodoxorubicin; 10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-; 3-(1,2-dihydroxyethyl)-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-L-lyxo-hexopyranoside; (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside hydrochloride (1:1) |
분자식 |
C27H32ClNO11 |
분자량 |
581.9961 |
InChI |
InChI=1/C27H31NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15-17,22,29-31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,16-,17-,22+,27-;/m0./s1 |
cas번호 |
141434-67-5 |
분자 구조 |
|
비등점 |
828.7°C at 760 mmHg |
인화점 |
455°C |
증기압 |
4.26E-29mmHg at 25°C |
위험성 표시 |
|
리스크 규칙 |
|
보안 규칙 |
|
|